Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 
 


Keywords

2025-08-12 16:00:00| Marketing Profs - Concepts, Strategies, Articles and Commentaries

This infographic looks at five key reasons journalists continue to love PR listicles: readability, ease, clickability, structure, and versatility. Read the full article at MarketingProfs


Category: Marketing and Advertising

 

LATEST NEWS

2025-08-12 07:15:00| TRENDWATCHING.COM

Noom's new weight-loss program formalizes what many have been experimenting with and hyping on Reddit and TikTok: microdosing GLP-1 drugs. The digital healthcare company has launched a Microdose GLP-1Rx Program priced at USD 119 to start, followed by USD 199 monthly, which includes both medication and a "GLP-1 Companion" behavior change platform. Noom's protocol uses doses that are 25% or less of standard maintenance doses, with 70% of members reporting no side effects while still achieving significant weight loss.The approach tackles three barriers to addressing obesity through Ozempic and its brethren: medication cost, side effects and sustainable behavior change. By personalizing dosing schedules to each member rather than following a one-size-fits-all approach, Noom aims to maximize outcomes while minimizing the digestive issues that lead many to abandon GLP-1 treatments. This strategy bridges the gap between DIY experimentation and conventional medical protocols, potentially making these medications accessible to those deterred by both high costs and unpleasant side effects.TREND BITEWhile early adopters chased dramatic transformations through high-dose protocols, mainstream consumers now gravitate toward gentler interventions. Microdosing is a sign of the "Ozempic era" maturing, with preferences shifting from dramatic transformations to sustainable lifestyle integration; think less "Biggest Loser" and more "Couch to 5K." With Noom repackaging GLP-1 medication as an accessible health tool for the masses, the drugs' impact on the food industry is likely to increase. (See "Ozempic Is Costing Grocery Stores Billions" and "Ozempic Is Shrinking Appetites. Restaurants Are Shrinking the Food.")


Category: Marketing and Advertising

 

2025-08-08 16:00:00| Marketing Profs - Concepts, Strategies, Articles and Commentaries

Catch up on select AI news and developments from the past week or so. Stay in the know. Read the full article at MarketingProfs


Category: Marketing and Advertising

 

Latest from this category

15.08Campaign turns in-game deaths into real-life organ donor registrations
14.08The Most Recommended Brands Globally and In the US [Infographic]
14.08Brand GRAVITY's Pull: Attracting B2B Byers Across Research Channels
13.08How Senior B2B Marketers Stay Sharp and Contribute as Their Roles Evolve
13.08How to Use Web Accessibility Standards to Optimize Your Conversion Rate
13.08Digital Dr Karl takes on climate skeptics with AI-powered persuasion
12.08The State of B2B Outbound Sales Outreach in 2025
12.08The PR Power of Listicles: Why Journalists Still Love It [Infographic]
Marketing and Advertising »

All news

15.08Kingsmill owner to buy Hovis to make UK bread giant
15.08Gatwick strikes suspended after new pay offer
15.08UK bioethanol industry faces collapse after government rejects rescue
15.08UK's Turing AI Institute responds to staff anger about defence focus
15.08U.S. stocks slide following inflation report, but world shares are mostly higher
15.08Shein's UK sales soar by a third
15.08Why is INTCs stock price up today? Trumps spat with Intel takes a surprising turn
15.08Trump and Putin meet on military base in Alaska for summit on Russia-Ukraine war
More »
Privacy policy . Copyright . Contact form .